

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{Folding box for 100 ml and 250 ml}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Flovuxin 300/16.5 mg/ml solution for injection for cattle

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each ml contains: 300 mg florfenicol and 16.5 mg flunixin (as flunixin meglumine).

3. PACKAGE SIZE

100 ml

250 ml

4. TARGET SPECIES

Cattle



5. INDICATION(S)

6. ROUTE(S) OF ADMINISTRATION

Subcutaneous use.



7. WITHDRAWAL PERIOD(S)

Withdrawal period(s):

Meat and offal: 46 days.

Milk: Not authorised for use in animals producing milk for human consumption. Do not use during lactation or drying off periods. Do not use in pregnant animals which are intended to produce milk for human consumption within 2 months of expected parturition

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 28 days.

Once broached use by.....

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.
Store in the original package.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

14. MARKETING AUTHORISATION NUMBER(S)

Vm 01656/5033

15. BATCH NUMBER

Lot {number}

16. SPECIAL WARNING(S), IF NECESSARY

17. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet

18. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE

POM-V ('To be supplied only on veterinary prescription')

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

{Glass bottles of 100 ml and 250 ml}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Flovuxin 300/16.5 mg/ml solution for injection for cattle

2. STATEMENT OF ACTIVE SUBSTANCES AND OTHER SUBSTANCES

Each ml contains: 300 mg florfenicol and 16.5 mg flunixin (as flunixin meglumine).

3. TARGET SPECIES

Cattle



4. ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Subcutaneous use.



5. WITHDRAWAL PERIOD(S)

Withdrawal period(s):

Meat and offal: 46 days.

Milk: Not authorised for use in animals producing milk for human consumption. Do not use during lactation or drying off periods. Do not use in pregnant animals which are intended to produce milk for human consumption within 2 months of expected parturition

6. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 28 days.

Once broached use by.....

7. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.

Store in the original package.

8. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

9. BATCH NUMBER

Lot {number}

10. PACKAGE SIZE

100 ml
250 ml

11. INDICATION(S)

12. SPECIAL WARNING(S), IF NECESSARY

13. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: Read package leaflet

14. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only.

POM-V ('To be supplied only on veterinary prescription')

15. MARKETING AUTHORISATION NUMBER(S)

Vm 01656/5033

B. PACKAGE LEAFLET

PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Flovuxin 300/16.5 mg/ml solution for injection for cattle

2. COMPOSITION

Each ml contains:

Active substances:

Florfenicol	300.0 mg
Flunixin (as flunixin meglumine)	16.5 mg

Excipients:

Propylene glycol E1520	150.0 mg
N-methylpyrrolidone	250.0 mg

Solution for injection is a clear, slightly yellow to yellow or to greenish yellow solution or to brownish yellow solution for injection.

3. TARGET SPECIES

Cattle

4. INDICATIONS FOR USE

Treatment of respiratory infections caused by *Mannheimia haemolytica*, *Pasteurella multocida*, *Mycoplasma bovis* and *Histophilus somni* associated with pyrexia.

5. CONTRAINDICATIONS

Do not use in adult bulls intended for breeding purposes.

Do not use in animals suffering from hepatic and renal diseases.

Do not use if there is a risk of gastrointestinal bleeding or in cases where there is evidence of altered hemostasis.

Do not use in animals suffering from cardiac diseases.

Do not use in cases of hypersensitivity to the active substances or to any of the excipients.

6. SPECIAL WARNING(S)

For Animal Treatment Only

Special precautions for use in animals:

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Official and local antimicrobial policies should be taken into account when the product is used.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to florfenicol.

Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided.

Repeated daily dosing has been associated with abomasal erosions in the pre-ruminant calf. The product should be used with caution in this age group.

The safety of the product has not been tested in calves of 3 weeks of age or less.

Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to enter wild fauna food chain. In case of death or sacrifice of treated animals, ensure that they are not made available to wild fauna.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This product may cause adverse effects. Care should be taken to avoid accidental self-injection.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Women of childbearing age, pregnant women or women suspected of being pregnant should use the veterinary medicinal product with serious caution to avoid accidental self-injection.

This veterinary medicinal product may cause hypersensitivity reactions (allergy). People with known hypersensitivity to propylene glycol and polyethylene glycols should avoid contact with the veterinary medicinal product. If you develop symptoms following exposure, such as skin rash, swelling of the face, lips or eyes or difficulty with breathing, you should seek medical advice immediately and show the package leaflet or the label to the physician.

Wash hands after use.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established in Cattle during pregnancy, lactation, or in animals intended for breeding. Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Concurrent use of other active substances that have a high degree of protein binding may compete with flunixin for binding and thus lead to toxic effects. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before the commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Gastrointestinal tract ulceration may be exacerbated by corticosteroids in animals given NSAIDs.

Overdose (symptoms, emergency procedures, antidotes):

Overdose studies in the target species for 3 times the duration of treatment showed decreased food consumption in the groups given 3 and 5 times the recommended dose. Decreased body weights were observed in the 5 times overdose group

(secondary to decreased food consumption). Decreased water consumption was observed in the 5 times overdose group. Tissue irritation increases with injection volume.

Treatment at 3 times the recommended treatment duration was associated with dose-related erosive and ulcerative abomasum lesions.

Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance:

For administration only by a veterinarian.

Major Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. ADVERSE EVENTS

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylactic-type reaction ¹
Undetermined frequency	Application site swelling ²

¹Those reactions might be fatal.

²Subcutaneous administration of the product may result in application site swelling that become palpable 2-3 days after injection. The duration of the application site swelling ranged from 15-36 days post-injection. Grossly, this is associated with minimal to mild irritation of the subcutis. Extension into the underlying muscle was noted in only a few instances. By 56 days post-dosing, no gross lesions were observed that would require any trim-out at slaughter.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system { <https://www.gov.uk/report-veterinary-medicine-problem> }.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous use.

40 mg of florfenicol per kg bodyweight and 2.2 mg of flunixin per kg bodyweight (equivalent to 2 mL of product per 15 kg body weight) to be administered by a single subcutaneous injection.

9. ADVICE ON CORRECT ADMINISTRATION

Swab septum before removing each dose. Use a dry sterile needle and syringe.

To ensure correct dosage and avoid underdosing, bodyweight should be determined as accurately as possible.

The dose volume given at any one injection site should not exceed 10 ml.
The cap may be safely punctured up to 25 times. When treating groups of animals in one run, use a draw-off needle that has been placed in the vial stopper to avoid excess broaching of the stopper. The draw-off needle should be removed after treatment.

The injection should only be given in the neck.

It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment 48 hours after injection. The anti-inflammatory component of this veterinary product, flunixin, may mask resistance to florfenicol in the first 24 hours after injection. If clinical signs of respiratory disease persist or increase, or if relapse occurs, treatment should be changed, using another antibiotic, and continued until clinical signs have resolved.

10. WITHDRAWAL PERIOD(S)

Meat and offal: 46 days.

Milk: Not authorised for use in animals producing milk for human consumption. Do not use during lactation or drying off periods. Do not use in pregnant animals which are intended to produce milk for human consumption within 2 months of expected parturition

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Do not store above 25 °C.
Store in the original package.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton after {EXP}. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days

When the container is broached/opened for the first time, using the in-use shelf-life which is specified on this package leaflet, the date on which any product remaining in the container should be discarded should be determined. This discard date should be written in the space provided.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Type II clear glass bottles of 100 ml and type I clear glass bottles of 250 ml with type I bromobutyl rubber stoppers and aluminium caps with plastic tear/flip-off tabs, in a cardboard box.

Package sizes:

Cardboard box containing 1 bottle of 100 ml.

Cardboard box containing 1 bottle of 250 ml.

Not all pack sizes may be marketed.

Vm 01656/5033

15. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST REVISED

June 2023

Find more product information by searching for the 'Product Information Database' or 'PID' on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder:

KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Slovenia

Manufacturer responsible for batch release:

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany


Local representatives and contact details to report suspected adverse reactions:

KRKA UK Ltd
Thames House,
Waterside Drive,
Langley,
SL3 6EZ
Phone +44 (0) 207 1646 156
E-mail info.uk@krka.biz

17. OTHER INFORMATION

Environmental properties

Flunixin is toxic to avian scavengers although foreseen low exposure leads to low risk.



Approved: 30 August 2023